Raphael Itzykson

MCU-PH

Université Paris Cité
Country flagFrance

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (15)

Year:

2026

Year:

2026

Year:

2026

Supplementary figure 1. Sequencing-based analysis of CNA and LOH in adult LH-ALL. Supplementary figure 2. Representation of mutations in the frequent targeted genes in adult LH-ALL. Supplementary figure 3. Longitudinal assessment of TP53-mutant cell fraction as determined by ddPCR along with clonal IG/TR-based MRD quantification in three patients with undetectable TP53 mutation at remission. Supplementary figure 4. Merged single-cell analysis of cell-surface markers by ADT-sequencing of remission samples from three LH-ALL patients. Supplementary figure 5. Individual single-cell analyses of cell-surface markers by ADT-sequencing of remission samples from three LH-ALL patients. Supplementary figure 6. Individual analyses of single-cell immunophenotyping and genotyping of remission samples from three LH-ALL patients. Supplementary figure 7. Evaluation of allelic dropout rate on heterozygous single nucleotide polymorphism (SNPs) in remission samples. Supplementary figure 8. Individual single-cell analysis of cell-surface markers by ADT-sequencing of diagnosis samples from three LH-ALL patients. Supplementary figure 9. Single-cell genotyping of heterozygous SNPs allowing LOH assessment in diagnosis samples from three LH-ALL patients. Supplementary Figure 10. Distribution of single-cell genotypes of two LH-ALL patients with persistent TP53 and JAK2 (EI_046) or DNMT3A (EI_035) mutations in remission samples.

Year:

2025

Supplementary Table 1. Karyotypes of LH-ALL patients at diagnosis. Supplementary Table 2. Somatic variants detected in LH-ALL patients at diagnosis. Supplementary Table 3. ARCH related variants detected in LH-ALL patients at remission. Supplementary Table 4. Minimal residual disease values of remission samples used for mutation analysis. Supplementary Table 5. Somatic alterations in cell populations from diagnostic samples (BMMC) based on single-cell analyses. Supplementary Table 6. Somatic alterations in FACS-sorted cell populations from diagnostic samples. Supplementary Table 7. Panel of genes for targeted sequencing. Supplementary Table 8. Single cell DNA amplicons for genotyping and LOH analyses. Supplementary Table 9. Single cell DNA amplicons for B-ALL clono-specific IG/TR detection. Supplementary Table 10. ADT-seq panel and spike-in antibodies. Supplementary Table 11. Single cell sequencing metrics.

Year:

2025

Purpose: PPM1D , a central regulator of the DNA damage response, is commonly mutated in therapy-related clonal hematopoiesis, acute myeloid leukemia (AML), and myelodysplastic syndromes (MDS). PPM1D mutations have been shown to expand under the selective pressure of DNA-damaging chemotherapy. However, whether PPM1D mutations promote the development of hematologic malignancies remains unclear. Experimental Design: We characterized the clinical and genomic profiles of 112 PPM1D -mutated patients across the spectrum of myeloid disorders using a combination of bulk and single-cell analyses on diagnostic and longitudinal samples. Results: Among all patients, 78% had a history of primary cancer, with DNMT3A and TP53 being the most frequently comutated genes. In 10 patients with high-grade serous ovarian cancer, longitudinal analysis showed variable dynamics of PPM1D -mutant clones, with 81% of clones expanding during exposure to alkylating agents. Clonal hierarchy estimation revealed that 44% of patients with PPM1D -mutated AML had a PPM1D mutation in the founder clone, with rare TP53 comutations. Both patients with TP53 wild-type and TP53 -mutated AML had poor overall survival. Single-cell DNA and surface protein analysis in seven patients confirmed that PPM1D mutations can arise in the founding clone and are associated with the expression of leukemic markers. Conclusions: PPM1D mutations found in clonal hematopoiesis can spontaneously regress after treatment discontinuation; however, they can also be found in the dominant clone in AML/MDS.

Year:

2025

Chronic myelomonocytic leukemia (CMML) is a heterogeneous disease presenting with either myeloproliferative or myelodysplastic features. Allogeneic hematopoietic cell transplantation (allo-HCT) remains the only potentially curative option, but the inherent toxicity of this procedure makes the decision to proceed to allo-HCT challenging, particularly because patients with CMML are mostly older and comorbid. Therefore, the decision between a nonintensive treatment approach and allo-HCT represents a delicate balance, especially because prospective randomized studies are lacking and retrospective data in the literature are conflicting. International consensus on the selection of patients and the ideal timing of allo-HCT, specifically in CMML, could not be reached in international recommendations published 6 years ago. Since then, new, CMML-specific data have been published. The European Society for Blood and Marrow Transplantation (EBMT) Practice Harmonization and Guidelines (PH&G) Committee assembled a panel of experts in the field to provide the first best practice recommendations on the role of allo-HCT specifically in CMML. Recommendations were based on the results of an international survey, a comprehensive review of the literature, and expert opinions on the subject, after structured discussion and circulation of recommendations. Algorithms for patient selection, timing of allo-HCT during the course of the disease, pretransplant strategies, allo-HCT modality, as well as posttransplant management for patients with CMML were outlined. The keynote message is, that once a patient has been identified as a transplant candidate, upfront transplantation without prior disease-modifying treatment is preferred to maximize chances of reaching allo-HCT whenever possible, irrespective of bone marrow blast counts.

Year:

2024

Year:

2024

Drug development for chronic myelomonocytic leukemia (CMML) has failed to parallel the recent success observed in related myeloid neoplasms. To address these shortcomings, the US Food and Drug Administration (FDA) held a “Mini-symposium on CMML: Current State of the Art and Trial Design” in September 2023. This symposium brought together a panel of key FDA regulators and academic experts in CMML drug development to discuss challenges and provide perspectives on future drug development for this disease. The panel explored unique challenges that underlie the lack of therapeutic advances in CMML to date and discussed relevant topics such as clinical trial design, study end points, and key regulatory considerations. This article summarizes the key points of discussion from this symposium to facilitate advancements in the field.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Collaborators (29)

Somedeb Ball

Vanderbilt University Medical Center

UNITED STATES
View details

Beat W. Schäfer

University Children's Hospital

SWITZERLAND
View details

Nicolas Boissel

Université Paris Cité

FRANCE
View details

Loew Damarys

Head of the Proteomic Mass Spec. Lab

Institut Curie

FRANCE
View details

Lina Benajiba

Université Paris Cité

FRANCE
View details

Kris Wood

Assistant/Associate/Full Professor (with tenure)

Duke University

UNITED STATES
View details

Vahid Asnafi

-

FRANCE
View details

Patrice Chevallier

-

FRANCE
View details

sylvain thepot

Université d'Angers

FRANCE
View details

David Fandrei

University Hospital Leipzig

GERMANY
View details

Norbert Vey

Head of the Leukemia and MDS Program/Pr

Institut Paoli-Calmettes

FRANCE
View details

Etienne Lengline

Assistance Publique - Hôpitaux de Paris

FRANCE
View details

Argiris Symeonidis

Professor of Hematology, Head of the Department

University of Patras School of Medicine

GREECE
View details

Sanam Loghavi

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Nathalie Droin

Inserm u1183

FRANCE
View details

Stéphanie Gachet

Chercheuse contractuelle

INSERM

FRANCE
View details

Pierre Fenaux

-

FRANCE
View details

ALEXANDRE PUISSANT

Principal Investigator, Tenured Associate Professor

-

FRANCE
View details

Elsa Bernard

Group Leader

Institut Gustave Roussy

FRANCE
View details

Melissa A. Fischer

Research Assistant Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Camille Lobry

Principal Investigator

-

FRANCE
View details

Jean-Baptiste Micol

Institut Gustave Roussy

FRANCE
View details

Nicolas Duployez

Assistant Professor

Université de Lille

FRANCE
View details

lionel adès

Professor

-

FRANCE
View details

Pau Montesinos

-

SPAIN
View details

Daniel Wiseman

The University of Manchester

UNITED KINGDOM
View details

Kimberly Stegmaier

Chair, Department of Pediatric Oncology

Dana-Farber Cancer Institute

UNITED STATES
View details

Carine Legrand

Research Center UMR 1342 (formerly Inserm/Cnrs U944/UMR7212 GenCellDis), Saint-Louis Hospital

FRANCE
View details

ILEANA ANTONY-DEBRE

INSERM

FRANCE
View details